Abstract
Accelerated atherosclerosis and microvascular complications are the leading causes of coronary heart disease, end-stage renal failure, acquired blindness and a variety of neuropathies, which could account for disabilities and high mortality rates in patients with diabetes. Glucagon-like peptide-1 (GLP-1) belongs to the incretin hormone family. L cells in the small intestine secrete GLP-1 in response to food intake. GLP-1 not only enhances glucose-evoked insulin release from pancreatic β-cells, but also suppresses glucagon secretion from pancreatic ??-cells. In addition, GLP-1 slows gastric emptying. Therefore, enhancement of GLP-1 secretion is a potential therapeutic target for the treatment of type 2 diabetes. Dipeptidyl peptidase-4 (DPP-4) is a responsible enzyme that mainly degrades GLP-1, and the half-life of circulating GLP-1 is very short. Recently, DPP-4 inhibitors and DPP-4-resistant GLP-1 receptor (GLP-1R) agonists have been developed and clinically used for the treatment of type 2 diabetes as a GLP-1-based medicine. GLP-1R is shown to exist in extra-pancreatic tissues such as vessels, kidney and heart, and could mediate the diverse biological actions of GLP-1 in a variety of tissues. So, in this paper, we review the pleiotropic effects of GLP-1-based therapies and its clinical utility in vascular complications in diabetes.
Keywords: AGEs, DPP-4, GLP-1, RAGE, diabetic vascular complications, atherosclerosis, insulin, pancreatic β-cells, pancreatic α-cells, glucagon
Current Pharmaceutical Design
Title: Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes
Volume: 17 Issue: 38
Author(s): Sho-ichi Yamagishi and Takanori Matsui
Affiliation:
Keywords: AGEs, DPP-4, GLP-1, RAGE, diabetic vascular complications, atherosclerosis, insulin, pancreatic β-cells, pancreatic α-cells, glucagon
Abstract: Accelerated atherosclerosis and microvascular complications are the leading causes of coronary heart disease, end-stage renal failure, acquired blindness and a variety of neuropathies, which could account for disabilities and high mortality rates in patients with diabetes. Glucagon-like peptide-1 (GLP-1) belongs to the incretin hormone family. L cells in the small intestine secrete GLP-1 in response to food intake. GLP-1 not only enhances glucose-evoked insulin release from pancreatic β-cells, but also suppresses glucagon secretion from pancreatic ??-cells. In addition, GLP-1 slows gastric emptying. Therefore, enhancement of GLP-1 secretion is a potential therapeutic target for the treatment of type 2 diabetes. Dipeptidyl peptidase-4 (DPP-4) is a responsible enzyme that mainly degrades GLP-1, and the half-life of circulating GLP-1 is very short. Recently, DPP-4 inhibitors and DPP-4-resistant GLP-1 receptor (GLP-1R) agonists have been developed and clinically used for the treatment of type 2 diabetes as a GLP-1-based medicine. GLP-1R is shown to exist in extra-pancreatic tissues such as vessels, kidney and heart, and could mediate the diverse biological actions of GLP-1 in a variety of tissues. So, in this paper, we review the pleiotropic effects of GLP-1-based therapies and its clinical utility in vascular complications in diabetes.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi and Matsui Takanori, Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes, Current Pharmaceutical Design 2011; 17 (38) . https://dx.doi.org/10.2174/138161211798999456
DOI https://dx.doi.org/10.2174/138161211798999456 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serum Bilirubin after Acute Ischemic Stroke is Associated with Stroke Severity
Current Neurovascular Research Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy The Role of Platelets in Cardiovascular Disease: Molecular Mechanisms
Current Pharmaceutical Design Poly(ADP)-Ribose Polymerase-1 Inhibitors as a Potential Treatment for Cocaine Addiction
CNS & Neurological Disorders - Drug Targets Naringenin and Atherosclerosis: A Review of Literature
Current Pharmaceutical Biotechnology Aspirin and Clopidogrel: A Sweeping Combination in Cardiology
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Signal Transduction Pathways Involved in the Chemo-Preventive Effect of Dietary Antioxidants: Study in HepG2 as a Cell Culture Model
Current Nutrition & Food Science Phenolic Content in Traditionally Processed Erythrina indica L. Seeds: Antioxidant Potential and Type II Diabetes Related Functionality
Current Nutrition & Food Science New Lipid-lowering Agents Acting on LDL Receptors
Current Topics in Medicinal Chemistry The Pathophysiology of Heart Failure in Children: The Basics
Current Cardiology Reviews Modulation of Stem Cell Differentiation by the Influence of Nanobiomaterials/ Carriers
Current Stem Cell Research & Therapy Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Current Pharmaceutical Design Prevention of Respiratory Syncytial Virus: A Review
Current Respiratory Medicine Reviews Non Steroidal Estrogen Antagonists: Current Status and Future Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews Analysis of the Selected Biochemical Blood Parameters in Patients After Total Hip Replacement
Current Rheumatology Reviews Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Cellular Cardiomyoplasty – Challenges of a New Era
Current Tissue Engineering (Discontinued) Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: A Systematic Review
Current Cardiology Reviews QT Prolongation and Anticancer Drugs: Is it a Cardiologist’s Worry? The Oncologist’s Point of View
Reviews on Recent Clinical Trials